Evidence mapPaperPMID 41334342Full record

ArticleFrontiers in nutrition2025

High-potency multi-strain probiotic formulations for safety and improvement of gastrointestinal function and intestinal health: a randomized controlled clinical trial.

Xinru Zhang, Ying Wu, Yiru Jiang, Jiajia Fan, Yao Dong, Shuguang Fang, Jianguo Zhu, Shaobin Gu

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinru Zhang *College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Ying Wu *College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Yiru JiangCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Jiajia FanCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Yao DongWecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou, China.
Shuguang FangWecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou, China.
Jianguo ZhuWecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou, China.
Shaobin GuCollege of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastrointestinal dysfunction is a prevalent condition affecting approximately 20-40% of the global population, substantially impairing quality of life. Probiotics have been shown to improve gastrointestinal health by modulating the intestinal microbiota, enhancing epithelial barrier function, and regulating immune responses. Methods: In this randomized controlled trial, 100 adults (aged 18-65 years) with gastrointestinal dysfunction, diagnosed according to the Citizen's Intestinal Health and Hygiene Guidelines from the Expert Consensus on Precision Health Communication in China, were enrolled. Participants were randomly assigned to receive either Wec600B (2 sachets/day, 600 billion CFU/sachet, 1,200 billion CFU/day) or Wec1000B (2 sachets/day, 1,000 billion CFU/sachet, 2000 billion CFU/day) for 4 consecutive weeks. Safety outcomes, gastrointestinal symptom improvement rate, immune and inflammatory biomarkers, intestinal barrier function, and gut microbiota diversity were assessed before and after the intervention. Results: After 4 weeks, both Wec600B and Wec1000B groups demonstrated significant improvement in gastrointestinal symptoms, including indigestion, abdominal pain, reflux, constipation, and diarrhea, without reported adverse events. Levels of fecal calprotectin (FC), neutrophil gelatinase-associated lipocalin (NGAL), and the pro-inflammatory marker FL were reduced, along with intestinal injury indicators such as diamine oxidase (DAO), D-lactic acid (D-LA), and lipopolysaccharide (LPS). In contrast, secretory IgA levels increased. Gut microbiota analysis revealed a significant increase in the relative abundance of beneficial genera, including Conclusion: Both Wec600B and Wec1000B high-potency probiotics improved gastrointestinal symptoms and enhanced intestinal health, likely through modulation of gut microbiota composition, reduction of inflammation, and reinforcement of intestinal barrier function.

Indexed as

gastrointestinal dysfunctiongut microbiotahigh-potency multi-strain probioticsmulti-strain probiotic formulationssafety evaluation

Identifiers

PMID41334342
PMCPMC12667431

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.